Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
The Biden administration is calling for a big boost for public health funding across the federal health department, but left out specific funding for Covid-19 activities. → Read More
The alliance says the federal drug discount program has expanded beyond its original mission to help low-income populations, and instead is benefiting large, well-resourced hospitals. → Read More
Pfizer CEO Albert Bourla made the maximum possible campaign contribution to Mehmet Oz ahead of his failed bid to represent Pennsylvania in the U.S. Senate. → Read More
The Biden administration wants to expand Democrats’ new drug pricing law by allowing Medicare to negotiate prices for more drugs. → Read More
Connecticut officials recruited diverse candidates to ensure people in underserved communities have access to advice about health insurance ahead of a major Medicaid transition. → Read More
“If you have to get cancer, it’s kind of a good one to have because it’s easy to remove," an oncologist said about President Biden's case. "This is an easily curable cancer that should not impact one’s quality of life, prognosis, or survival.” → Read More
The Biden administration is pitching three new experiments aimed at bringing down drug prices for Medicare and Medicaid patients. → Read More
Medicare advisers want to tweak a process that has been used to restrict access to new Alzheimer’s drugs. → Read More
Citing STAT's reporting, Sen. Tammy Baldwin questioned whether Ascension is using the returns from its for-profit investments to help patients. → Read More
The Biden administration offered the first glimpse into how it’s planning to enact a new law that will penalize drugmakers for hiking their prices faster than inflation. → Read More
Medicare enrollees will pay more for Covid tests after the public health emergency ends, according to the agency that oversees the program. → Read More
Biotech investors don’t often lay out their strategies, but one offered a rare glimpse into what he's doing after Democrats empowered Medicare to negotiate drug prices. → Read More
Former Senate health committee Republican leader Richard Burr will be starting a new health care practice at a well-known Washington law and lobbying firm. → Read More
As hospitals worry that payments from federal health programs could be slashed, the New York lobby's relationships could come in handy. → Read More
WASHINGTON — It’s not every day that the pharmaceutical industry, the NAACP, a cancer center, and a nonpartisan think tank are all lobbying to achieve the → Read More
PhRMA has terminated its contract with Jeff Ricchetti, a lobbyist who is the brother of a prominent Biden White House official. → Read More
HHS oversight of research that could enhance dangerous pathogens has vague parameters and a lack of transparency, a federal watchdog found. → Read More
HHS laid out a detailed timeline of when the public can weigh on on the agency’s new Medicare drug price negotiation program. → Read More
Despite the many failures of our Covid response, very little about U.S. pandemic infrastructure has changed. But some are still working to find compromise reforms. → Read More
HHS will get to decide how to pay hospitals in the 340B program for more than $1 billion in illegal underpayments, a federal court ruled. → Read More